These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34960134)

  • 1. Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults.
    Eiden J; Gordon G; Fierro C; Herber R; Aitchison R; Belshe R; Greenberg H; Hoft D; Hatta Y; Moser MJ; Tary-Lehmann M; Kawaoka Y; Neumann G; Radspinner P; Bilsel P
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults.
    Eiden J; Fierro C; Schwartz H; Adams M; Ellis KJ; Aitchison R; Herber R; Hatta Y; Marshall D; Moser MJ; Belshe R; Greenberg H; Coelingh K; Kawaoka Y; Neumann G; Bilsel P
    J Infect Dis; 2022 Dec; 227(1):103-112. PubMed ID: 36350017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.
    Eiden J; Fierro C; White A; Davis M; Rhee M; Turner M; Murray B; Herber R; Aitchison R; Marshall D; Moser MJ; Belshe R; Greenberg H; Coelingh K; Kawaoka Y; Neumann G; Bilsel P
    Lancet Infect Dis; 2024 Oct; 24(10):1118-1129. PubMed ID: 39004096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2018 Aug; 36(33):5097-5103. PubMed ID: 30007825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice.
    Sarawar S; Gabaglia CR; Sanchez A; Hatta Y; Dias P; Neumann G; Kawaoka Y; Bilsel P
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain.
    Eiden J; Volckaert B; Rudenko O; Aitchison R; Herber R; Belshe R; Greenberg H; Coelingh K; Marshall D; Kawaoka Y; Neumann G; Bilsel P
    J Infect Dis; 2022 Aug; 226(1):83-90. PubMed ID: 34323977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults.
    Hill-Batorski L; Weiner JA; Ackerman ME; Hatta Y; Hoft DF; Herber R; Moser MJ; Bilsel P
    J Infect Dis; 2024 Jul; ():. PubMed ID: 39012796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge.
    Hill-Batorski L; Hatta Y; Moser MJ; Sarawar S; Neumann G; Kawaoka Y; Bilsel P
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants.
    Moser MJ; Hill-Batorski L; Bowen RA; Matejka SM; Marshall D; Kawaoka Y; Neumann G; Bilsel P
    Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.
    Rudenko L; Kiseleva I; Naykhin AN; Erofeeva M; Stukova M; Donina S; Petukhova G; Pisareva M; Krivitskaya V; Grudinin M; Buzitskaya Z; Isakova-Sivak I; Kuznetsova S; Larionova N; Desheva J; Dubrovina I; Nikiforova A; Victor JC; Neuzil K; Flores J; Tsvetnitsky V; Kiselev O
    PLoS One; 2014; 9(2):e87962. PubMed ID: 24533064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.
    Pan SC; Hsieh SM; Lin CF; Hsu YS; Chang M; Chang SC
    Vaccine; 2019 Mar; 37(14):1994-2003. PubMed ID: 30837170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
    Nicolodi C; Groiss F; Kiselev O; Wolschek M; Seipelt J; Muster T
    Vaccine; 2019 Jun; 37(28):3722-3729. PubMed ID: 31155415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
    Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
    Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.
    Treanor JJ; Schiff GM; Hayden FG; Brady RC; Hay CM; Meyer AL; Holden-Wiltse J; Liang H; Gilbert A; Cox M
    JAMA; 2007 Apr; 297(14):1577-82. PubMed ID: 17426277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
    Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K
    Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.
    Halperin SA; Smith B; Clarke K; Treanor J; Mabrouk T; Germain M
    Hum Vaccin; 2005; 1(1):37-42. PubMed ID: 17038827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.